ClinicalTrials.gg

Program

befotertinib

Also written as “Befotertinib”, “D-0316” and “D-0316 Capsule”.

Its studies are mostly in Carcinoma, Non-Small-Cell Lung, led by 2 companies.

Furthest: phase 3, since Dec 10, 20196 company-led studies, 2 open or runningNext primary completion: Nov 2028 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Betta Pharmaceuticals42 open or runningphase 3since Dec 10, 2019Dec 10, 2019Nov 2028phase 2 · NCT07181499
InventisBio20 open or runningphase 2since Mar 1, 2019Feb 13, 2018none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Feb 13, 2018First study: phase 1 study in Advanced Non Small Cell Lung CancerNew to InventisBioInventisBio · NCT03452150 · 84 enrolled · China
  2. Mar 1, 2019Phase 2 study in Solid TumorInventisBio · NCT03861156 · 290 enrolled · China
  3. Dec 10, 2019Betta Pharmaceuticals's first study: phase 3 study in Carcinoma, Non-Small-Cell LungNew to Betta PharmaceuticalsBetta Pharmaceuticals · NCT04206072 · 362 enrolled · China
  4. Jul 3, 2020Phase 1 study in Advanced or Metastatic Non-small Cell LungBetta Pharmaceuticals · NCT04464551 · 4 enrolled · China
  5. Aug 8, 2021Phase 2 study in Carcinoma, Non-Small-Cell LungBetta Pharmaceuticals · NCT05007938 · 30 enrolled · China
  6. Sep 10, 2025Phase 2 study in NSCLCBetta Pharmaceuticals · NCT07181499 · 28 planned · China

Ahead

  1. Nov 2028Primary completion: phase 2 study in NSCLCBetta Pharmaceuticals · NCT07181499

TargetBeta

EGFR →read by rule
“An orally available inhibitor of the epidermal growth factor receptor (EGFR) mutant form T790M, ”NCIt, by rule

Other programs on EGFR

ProgramCompanyFurthest phaseStudies
izalontamab brengitecanSichuan Biokin Pharmaceuticalphase 355
pimurutamabFosun Pharmaphase 317
Anti-EGFR Antibody-drug Conjugate CPO301CSPC Pharmaceutical Groupphase 316
sunvozertinibruleDizal Pharmaceuticalsphase 312
becotatugCSPC Pharmaceutical Groupphase 311
andamertinibruleavistone-biotechnology-co-ltdphase 310
becotatug vedotinrulelepu-biopharma-co-ltdphase 310
sevabertinibruleBayerphase 38
HS-10504Hansoh Pharmaceutical Groupphase 37
petosemtamabruleGenmabphase 36
bafisontamabruleshanghai-epimab-biotherapeutics-co-ltdphase 35
zipalertinibruleOtsukaphase 34

Studies

All 6 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07181499NSCLC · China2RecruitingBetta PharmaceuticalsNov 202828
NCT05007938Carcinoma, Non-Small-Cell Lung · China2Active, not recruitingBetta PharmaceuticalsDec 31, 202430
NCT04464551Advanced or Metastatic Non-small Cell Lung · China1UNKNOWNBetta PharmaceuticalsAug 20214
NCT04206072Carcinoma, Non-Small-Cell Lung · China3CompletedBetta PharmaceuticalsJul 30, 2022362
NCT03861156Solid Tumor · China2CompletedInventisBioAug 15, 2021290
NCT03452150Advanced Non Small Cell Lung Cancer · China1CompletedInventisBioAug 28, 202084

How it is read

Names in the registry

  • “Befotertinib”, 2 entries
  • “D-0316”, 2 entries
  • “D-0316 Capsule”, 1 entry
  • “[14C]D-0316 suspension”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.